Vermillion's Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Sta...( - Multiple Studies Presented at Soci...),Health

- Multiple Studies Presented at Society of Gynecologic Oncologists' Annual

Meeting on Women's Cancer -

FREMONT, Calif. and TAMPA, Fla., March 10 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRMLD), a molecular diagnostics company, presented data from several studies demonstrating the benefits of the Company's ovarian cancer protein biomarker panel. The data suggest that use of Vermillion's biomarkers could help better identify women with ovarian cancer, as well as improve the detection of early-stage disease. Results of these studies were presented at the Society of Gynecologic Oncologists' (SGO) 39th Annual Meeting on Women's Cancer in Tampa, Florida (Posters 080, 135, 175).

"The data presented today continue to confirm the potential of our biomarkers to distinguish between benign and malignant tumors and diagnose early-stage disease," said Eric T. Fung, M.D., Ph.D., Chief Scientific Officer of Vermillion.

Further Evidence Supporting Ovarian Tumor Triage Test (Poster 135)

A clinical study examining Vermillion's marker panel for ovarian cancer provided independent validation that it can distinguish malignant tumors from benign pelvic masses. Results of the study demonstrated that the biomarker panel could more than double the number of ovarian cancer cases referred to a gynecologic oncologist, thereby improving survival rates and reducing the number of surgeries performed.

A model comprising the Company's biomarker panel was trained on a set of 270 samples from the University of Kentucky. This model was then tested in a prospectively collected cohort of 709 women from Rigshospitalet in Copenhagen, Denmark. Vermillion's model demonstrated portability from the training set to
'/>"/>